Crinetics Pharmaceuticals Inc
Chiusa
SettoreSettore sanitario
84.95 0.13
Panoramica
Variazione del prezzo dell'azione
24h
Minimo
84.95
Massimo
84.95
Entrata | 7M -121M |
|---|---|
Vendite | 14M 25M |
EPS | -1.14 |
Margine di Profitto | -481.149 |
Dipendenti | 594 |
EBITDA | -4.7M -131M |
Raccomandazioni | Neutrale |
|---|---|
Previsioni per 12 mesi | +0.72% upside |
Capitalizzazione di Mercato | 148M 9B |
|---|---|
Apertura precedente | 84.82 |
Chiusura precedente | 84.95 |
Crinetics Pharmaceuticals Inc Grafico
Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.
Notizie correlate
Confronto tra pari
Modifica del prezzo
Crinetics Pharmaceuticals Inc Previsione
Obiettivo di Prezzo
By TipRanks
0.72% in crescita
Previsioni per 12 mesi
Media 85.56 USD 0.72%
Alto 95 USD
Basso 80 USD
Basato su 11 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Crinetics Pharmaceuticals Inc - Dist negli ultimi 3 mesi.
Notizie finanziarie
$
Chi Siamo Crinetics Pharmaceuticals Inc
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
